On October 14, 2021 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results, and provide a corporate update (Press release, Moderna Therapeutics, OCT 14, 2021, View Source [SID1234591245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 9177025. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

On October 14, 2021 4SC AG (4SC, FSE Prime Standard: VSC) reported that it will attend and present at the European Organisation for Research and Treatment of Cancer Conference (EORTC) Cutaneous Lymphoma Group 20-21 Meeting in Marseille, France, from 14-16 Oct 2021 (Press release, 4SC, OCT 14, 2021, View Source [SID1234591244]). The posters will be available on 4SC’s website after the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A summary of the posters is listed below.

Poster – RESMAIN study update: RESMAIN study – Evaluating resminostat for maintenance treatment of patients with advanced stage (Stage IIB‑IVB) mycosis fungoides (MF) or Sézarysyndrome (SS)
Poster – Scientific data from research exploring the mode-of-action of resminostat: Mode-of-action of HDAC inhibitor resminostat in CTCL cells

On October 14, 2021 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company’s business and outlook on Thursday, Oct. 28, at 4:30 p.m. ET (Press release, PTC Therapeutics, OCT 14, 2021, https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-host-conference-call-discuss-third-quarter-2021 [SID1234591241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing (877) 303-9216 (in the United States) or (973) 935-8152 (outside of the United States) five minutes prior to the start of the call and providing the passcode 8574103. A live, listen-only webcast of the conference call can be accessed on the investor section of the PTC website at View Source A replay of the call will be available approximately two hours after completion of the call and will be archived on the company’s website for 30 days following the call.

On October 14, 2021 Veracyte, Inc. (Nasdaq: VCYT) reported that new data further validating the clinical utility of the company’s Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 taking place October 24-27, 2021, in Chicago (Press release, Veracyte, OCT 14, 2021, View Source [SID1234591240]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In two, separate oral presentations, investigators will share findings from studies that assessed the Decipher Prostate test in multiple, large Phase 3 randomized trials. The studies evaluated the test’s utility in patients with newly diagnosed, clinically high-risk prostate cancer receiving definitive radiotherapy as well as among patients experiencing biochemical disease progression following radical prostatectomy.

"The Decipher Prostate data that will be shared at this year’s ASTRO meeting provide exciting new evidence that the test could positively and profoundly impact shared decision-making, resulting in individualized treatment decisions in both the post-biopsy and post-prostatectomy prostate cancer settings," said Tina Nova, Ph.D., Veracyte’s general manager, Thyroid and Urologic Cancers.

Following are details of the abstract presentations:

Dates/Times:

Media Briefing: Monday, October 25, 9:30 – 10:30 a.m. CT

Oral Presentation: Tuesday, October 26, 8:35 a.m. CT

Title:

Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer

Abstract #:

95 (oral presentation)

Presenter:

Paul L. Nguyen, M.D., Dana-Farber / Brigham and Women’s Cancer Center

Location:

McCormick Place West, Room W181 a/b/c

Date/Time:

Tuesday, October 26, 8:25 a.m. CT

Title:

Performance of a Genomic Classifier (GC) within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) after Radical Prostatectomy (RP)

Abstract #:

94 (oral presentation)

Presenter:

Alan Dal Pra, M.D., University of Miami – Sylvester Cancer Center

Location:

McCormick Place West, Room W181 a/b/c

On October 14, 2021 Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) reported that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer (Press release, Exelixis, OCT 14, 2021, View Source [SID1234591238]). The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Exelixis will pay STORM an upfront fee of $17 million in exchange for licensing two of STORM’s discovery programs targeting RNA modifying enzymes, including ADAR1, as well as provide funding for discovery research activities conducted or managed by STORM. Exelixis will be solely responsible for global development, manufacturing and commercialization activities of any resulting molecules. STORM will be eligible for development, regulatory and commercialization milestones, as well as tiered royalties on the annual net sales of any compounds that are successfully commercialized under the collaboration.

"ADAR1 holds tremendous promise as a novel target for cancer. However, discovery efforts to identify ADAR1 inhibitors have remained a challenge, notably the development of rigorous, relevant assays to support small molecule drug discovery," said Peter Lamb, Ph.D., Executive Vice President, Scientific Strategy and Chief Scientific Officer, Exelixis. "STORM has extensive expertise in RNA-modifying enzymes and has successfully developed advanced mass spectrometry-based high-throughput screening assays and implemented a suite of technologies to enable the discovery of ADAR1 inhibitors. We believe this collaboration has the potential to expand our portfolio of differentiated small molecule therapies in the field of oncology and deliver a first-in-class ADAR1 inhibitor."

"STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes. This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics. "Exelixis has a proven history of success in the discovery, development and commercialization of innovative small molecule cancer therapies to provide patients with clinically meaningful treatment options. Access to Exelixis’ development expertise and funding will enable more rapid advancement of our ADAR1 discovery program, as well as other target activities under the collaboration."

ADAR1 edits double-stranded RNA (dsRNA) molecules, reducing their ability to activate innate immunity. Depletion or inhibition of ADAR1 can activate the innate immune response in tumor cells, which can trigger tumor cell death. Notably, up to 30% of tumor cells in The Cancer Genome Atlas have high interferon-stimulated gene signatures and may be dependent on ADAR1, suggesting that ADAR1-targeted therapies could have potential in a wide variety of solid tumors as a single agent therapy. In addition, ADAR1 inhibition may also sensitize tumors to immune checkpoint inhibition and overcome mechanisms of resistance to this class of therapies.